: Usana sees sales bump in China, but 2023 still uncertain

by | Jan 5, 2023 | Stock Market

Usana Health Sciences Inc. shares fell more than 4% in the extended session Thursday after the multi-level marketing company called for lower 2023 sales and profit than Wall Street expected, saying it is unsure whether an uptick in sales at the end of 2022 would last. Usana
said it expects sales between $850 million and $950 million for fiscal 2023, and per-share earnings between $2.35 and $3.30 for the year. That compares with FactSet consensus of sales of $974 million and EPS of $3.35 for 2023.

Usana, which is scheduled to report full fourth-quarter results on Feb. 7 after market close, also released preliminary fourth-quarter and fiscal 2022 earnings. See also: Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab It called for sales of about $995 million in 2022, and EPS around $3.65 for the year. That compares with FactSet consensus for $1.19 billion in sales and EPS of $3.28 for 2022. Usana had guided for 2022 sales between $955 million and $975 million, and EPS between $3.15 and $3.40. The company said it had about 490,000 total active customers at the end of 2022, with fourth-quarter sales as well as full-year sales benefitting from sales in mainland China during the last two weeks of the year. That was thanks to “increased demand for certain products following the unanticipated shift in COVID policy in this market,” the company said. While the sales bump contributed to the company’ …

Article Attribution | Read More at Article Source

Share This